The initial reports showed that BLU-945 alone or in combination with osimertinib demonstrated early signals of clinical activity and was well tolerated in heavily pretreated EGFR-mutant NSCLC patients [200]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.